What changed
$SNY — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $3.1B | EPS $1.10 vs $1.03 🟢
💡 Consensus expected EPS of $1.03, but actual was $1.10—a 7% beat. The market may be pricing in declining legacy drug sales too severely, ignoring contribution from newer products and cost controls. We see continued earnings momentum driving positive revisions and closing the valuation gap versus the sector median P/E of ~15.
📉 Reward/risk: 2.0:1
🏢 Business Quality: 7/10
📊 Valuation: cheap — P/E of 9.4 based on annualized Q1 EPS; compared to large-cap pharma peers trading at 13-18x, SNY is at a significant discount.
🔮 Catalyst: Q1 2026 earnings beat (reported recently)
💰 Entry: $41.33, stop $39.26, target $45.46
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/SNY0625